ClinicalTrials.gg
CompletedNCT00945763Updated Dec 2, 2011

Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery

A Phase 2 interventional study of N1539 and placebo in Dental Pain, sponsored by Alkermes, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-12-02.

Sponsored by Alkermes, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
230
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Toothache with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Toothache · United States.

Enrollment
20th of 50
230 · median 194
Started
2009
with 9 others
Phase 2
20 of 54
none open now
Registered
11th of 54
by date

Among the 54 studies in Toothache with a site in United States, this one is the 20th largest by enrollment of the 50 interventional ones that give a count, is one of 10 that started in 2009, is one of 20 in phase 2, and was the 11th registered.

Toothache

142 studies on the registry are indexed under Toothache; 28 are open to participants now.

Browse Toothache studies →

Open to participants now

6 of the 54 studies in Toothache with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 15 Toothache studies recruiting now, 4 (27%) set no upper age limit and 11 (73%) stop at 75 or younger; 7 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Toothache with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of single IV doses of N1539 after dental impaction surgery.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, single center study in subjects who have undergone third molar extraction surgery. Eligible subjects will have surgical removal of >2 third molars, of which at least 1 must be a complete or partial mandibular impaction. Each subject's study participation will consist of a screening visit (1-21 days prior to surgery), an inpatient evaluation period of 24 hours following dosing, and a follow-up phone call 3-5 days postdose.

03

Conditions studied

  • Dental Pain

Browse trials for

Keywords

  • Dental Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • surgical extraction of > 2 third molars with at least 1 complete or partial mandibular bony extraction

Exclusion criteria

Exclusion Criteria:

  • allergic response to aspirin, NSAIDs, acetaminophen or hydrocodone
  • use of aspirin or other analgesics within 48 hours prior to surgery
  • current or recent history of drug or alcohol abuse
  • any medication for treatment of chronic pain
  • abnormality on screening laboratory test active or recent history of peptic ulcer disease or GI bleeding
  • prior abdominal surgery, except uncomplicated appendectomy
  • any other surgical procedure within 30 days before administration of study drug
  • pregnancy or breastfeeding
  • untreated hypertension; SBP > 140 mmHg or DBP > 95 mmHg
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
230 participants (actual)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Experimental
    N1539 15 mg

    Drug: N1539

  • Experimental
    N1539 30 mg

    Drug: N1539

  • Experimental
    N1539 60 mg

    Drug: N1539

  • Active comparator
    Motrin

    Drug: Motrin

Interventions

  • DrugN1539

    30 mg

    Also known as: meloxicam

  • Drugplacebo

    tablets

    Also known as: sugar pill

  • DrugN1539

    15 mg

    Also known as: meloxicam

  • DrugN1539

    60 mg

    Also known as: meloxicam

  • DrugMotrin

    400 mg

    Also known as: ibuprofen

06

What researchers measure

Primary outcomes

  1. Pain Intensity Difference at End of Study

    Time frame: 0-24 hours

Secondary outcomes

  1. Onset of action

    Time frame: 0-1 hour

07

Study locations

1 site
  • Jean Brown Research
    Salt Lake City, Utah 84124, United States
08

References and documents

Publications

  • Viscusi ER, Gan TJ, Bergese S, Singla N, Mack RJ, McCallum SW, Du W, Hobson S. Intravenous meloxicam for the treatment of moderate to severe acute pain: a pooled analysis of safety and opioid-reducing effects. Reg Anesth Pain Med. 2019 Mar;44(3):360-368. doi: 10.1136/rapm-2018-100184. Epub 2019 Feb 7. PubMed 30737315 ↗
  • Christensen SE, Cooper SA, Mack RJ, McCallum SW, Du W, Freyer A. A Randomized Double-Blind Controlled Trial of Intravenous Meloxicam in the Treatment of Pain Following Dental Impaction Surgery. J Clin Pharmacol. 2018 May;58(5):593-605. doi: 10.1002/jcph.1058. Epub 2018 Jan 12. PubMed 29329493 ↗

Related links

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2009
First posted
Jul 24, 2009
Start
Jul 2009
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Results delay requested
Jun 24, 2011
Last update
Dec 2, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00945763
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2009
Start date
Jul 2009
Primary completion
Nov 2009
Completion
Nov 2009
Last update
Dec 2, 2011

Study contacts

Steven Christensen, DDS
principal investigator · Jean Brown Research, Salt Lake City, UT 84124

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion